Skip to main content

CIMR debates in Public Policy: Getting innovation into the NHS: How can we improve?

When: —
Venue: Hybrid

Book your place

The (relatively) new Government is starting to reveal how it intends to keep the UK healthy, with the NHS Ten Year plan expected in June and a Ten Year cancer plan also pending. The country has a strong reputation for invention and innovation in medicines and medical devices, developing both better treatments and ways to make the NHS more efficient. Organisations such as the National Institute for Health and Care Research (NIHR) help fund medical research priorities and encourage the public to take part in research.

However, for reasons of finance, policy and implementation, it’s not straightforward to introduce new products and approaches rapidly into the unique system that is the NHS. What policies are needed to align our research and innovation culture with the health of the nation? In this session we will hear from a start-up looking to make clinical trial recruitment more efficient, a Health Innovation Network working on adoption of innovation into the NHS, the NIHR and a healthcare venture capital firm on the attractiveness of the UK as a commercial market for biotech and medtech products.

Please note: if you are attending online, you will be emailed a Teams link prior to the event, which will take you to the online event.

Contact name: Wendy Tuxworth

Speakers
  • Denis Talbot —

    Denis Talbot is Emeritus Professor of Cancer Medicine and consultant medical oncologist at the University of Oxford. As Chief Investigator for national and international clinical trials he led studies in phase I, II and III cancer trials (H Index 42). He is Chairman of the Board of Trustees of the British Thoracic Oncology Group, the largest organisation of its type in Europe, and is a member of the Lung Cancer Clinical Experts Group. He serves on Safety, Data Monitoring and Scientific Advisory Boards for clinical trials, and is Advisor for the Foulkes Foundation and Clinical Net.

    Clinical Net is developing a platform designed to digitalise and automate clinical trial processes in order to facilitate access for patients, improve trial recruitment and success rate, and ultimately reduce costs and accelerate time associated with drug development.

  • Julie Hart —

    Julie Hart is co-Founder and Chief Medical Officer of Astratus Limited, a diagnostics company developing rapid antimicrobial susceptibility testing technology to support same-day treatment decisions and combat antimicrobial resistance. With more than 30 years of experience in healthcare innovation, diagnostics, medical affairs, and commercialisation, Julie has advised the NHS, healthcare organisations, policy makers, and regulatory agencies on technology adoption and healthcare transformation. A former NHS innovation and commercialisation lead, she specialises in translating emerging technologies into clinical practice and driving adoption across complex healthcare systems. Julie is a recognised speaker on diagnostics innovation and healthcare technology adoption, engaging audiences across industry, investment, clinical practice, and health policy.

  • Michelle Blake —

    Michelle Blake is an Associate Director and Senior Regulatory Consultant at DLRC Regulatory Consultancy, with 15 years’ experience guiding medicines from first-in-human studies through to marketing authorisation and beyond. She has deep expertise in clinical trial strategy, paediatric and orphan drug development, working across oncology, rare diseases, ATMPs and medical innovation. Michelle also leads regulatory teams supporting global pharma and biotech companies and is an active contributor to the regulatory community through TOPRA as an award recipient, masterclass lecturer and symposium working party member.

  • Nuria Coll Bastus —

    Nuria is founder and CEO of Clinical Net. Her background bridges science, research, and strategy. She holds a BSc in Chemistry, MRes in Organic Chemistry, MSc in Cancer Therapeutics and a PhD in Oncogenomics, followed by postdoctoral work in molecular biology. She later pursued an Executive MBA in order to lead healthcare innovation from both scientific and business perspectives. She is a certified GDPR practitioner, ensuring that the company’s work is built with data ethics and regulatory compliance at its core.

  • Paul Edwards, MBE —

    Paul Edwards MBE is Managing Partner & Board Member of SCI Partners, a former Chair of OBN (UK) Ltd (Now BioUK), now Non-Executive Director of BioUK). Specialising in international, senior level and board appointments across the life science, pharmaceutical, generics and medical device sectors, Paul has a track record of executive roles within a succession of innovative companies. A graduate chemist with over 40 years in the industry, Paul has led many successful enterprises, both commercially and scientifically. His successes include preparing an exit strategy and final valuation at £230m for BioProducts Laboratory and working on cancer precision therapies as board advisor and interim CEO of NanoMab Technology Ltd.

Tags: